Joaquı́n Mateo

24.2k total citations · 5 hit papers
148 papers, 6.1k citations indexed

About

Joaquı́n Mateo is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Joaquı́n Mateo has authored 148 papers receiving a total of 6.1k indexed citations (citations by other indexed papers that have themselves been cited), including 103 papers in Pulmonary and Respiratory Medicine, 84 papers in Oncology and 53 papers in Cancer Research. Recurrent topics in Joaquı́n Mateo's work include Prostate Cancer Treatment and Research (85 papers), PARP inhibition in cancer therapy (52 papers) and Cancer Genomics and Diagnostics (35 papers). Joaquı́n Mateo is often cited by papers focused on Prostate Cancer Treatment and Research (85 papers), PARP inhibition in cancer therapy (52 papers) and Cancer Genomics and Diagnostics (35 papers). Joaquı́n Mateo collaborates with scholars based in United Kingdom, Spain and United States. Joaquı́n Mateo's co-authors include Johann S. de Bono, David Olmos, Shahneen Sandhu, Karim Fizazi, Neal D. Shore, Oliver Sartor, Fred Saad, Neeraj Agarwal, Antoine Thiery-Vuillemin and Carrie A. Adelman and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and Nature Medicine.

In The Last Decade

Joaquı́n Mateo

142 papers receiving 6.0k citations

Hit Papers

Olaparib for Metastatic C... 2018 2026 2020 2023 2020 2019 2020 2018 2022 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Olaparib for Metastatic Castration-Resistant Prostate Cancer
    2020 1.4k citations Johann S. de Bono, Joaquı́n Mateo et al. New England Journal of Medicine profile →
  2. A decade of clinical development of PARP inhibitors in perspective
    2019 495 citations Joaquı́n Mateo, Christopher J. Lord et al. Annals of Oncology profile →
  3. Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
    2020 474 citations Maha Hussain, Joaquı́n Mateo et al. New England Journal of Medicine profile →
  4. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
    2018 391 citations Joaquı́n Mateo, Debyani Chakravarty et al. Annals of Oncology profile →
  5. Delivering precision oncology to patients with cancer
    2022 197 citations Joaquı́n Mateo, Lotte Steuten et al. Nature Medicine profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Joaquı́n Mateo 3.3k 3.2k 2.1k 1.8k 742 148 6.1k
Eleni Efstathiou 2.4k 0.7× 4.7k 1.5× 2.0k 1.0× 1.7k 0.9× 1.3k 1.7× 203 7.4k
Kyung-Hun Lee 4.1k 1.2× 2.0k 0.6× 1.6k 0.8× 1.5k 0.8× 382 0.5× 216 6.0k
Rinat Yerushalmi 4.4k 1.3× 1.8k 0.6× 2.2k 1.0× 2.3k 1.2× 495 0.7× 119 6.7k
Daniele Generali 3.1k 0.9× 1.7k 0.5× 2.5k 1.2× 2.1k 1.1× 490 0.7× 232 6.2k
Przemyslaw Twardowski 2.2k 0.7× 2.4k 0.8× 1.6k 0.7× 1.2k 0.7× 464 0.6× 113 4.3k
Åslaug Helland 2.7k 0.8× 2.3k 0.7× 2.7k 1.3× 1.8k 1.0× 402 0.5× 190 6.0k
Binghe Xu 6.1k 1.8× 2.8k 0.9× 3.2k 1.5× 3.0k 1.6× 682 0.9× 387 9.1k
Niven Mehra 2.3k 0.7× 2.6k 0.8× 1.5k 0.7× 1.3k 0.7× 775 1.0× 178 4.4k
Eva Ciruelos 5.3k 1.6× 2.3k 0.7× 1.5k 0.7× 2.4k 1.3× 1.5k 2.0× 208 7.1k
Martin Filipits 4.3k 1.3× 3.1k 1.0× 2.9k 1.4× 2.7k 1.5× 382 0.5× 200 8.0k

Countries citing papers authored by Joaquı́n Mateo

Since Specialization
Citations

This map shows the geographic impact of Joaquı́n Mateo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joaquı́n Mateo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joaquı́n Mateo more than expected).

Fields of papers citing papers by Joaquı́n Mateo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joaquı́n Mateo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joaquı́n Mateo. The network helps show where Joaquı́n Mateo may publish in the future.

Co-authorship network of co-authors of Joaquı́n Mateo

This figure shows the co-authorship network connecting the top 25 collaborators of Joaquı́n Mateo. A scholar is included among the top collaborators of Joaquı́n Mateo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joaquı́n Mateo. Joaquı́n Mateo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Viaplana, Cristina, Joaquı́n Mateo, Francesc Salvà, et al.. (2025). A CT-based deep learning-driven tool for automatic liver tumor detection and delineation in patients with cancer. Cell Reports Medicine. 6(4). 102032–102032. 3 indexed citations
3.
Aguilar, Daniel, Sara Arce‐Gallego, Irene Casanova‐Salas, et al.. (2025). Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer. Molecular Cancer Therapeutics. 24(12). 1959–1976. 1 indexed citations
4.
5.
Mateo, Joaquı́n, et al.. (2025). Impact of gold nanoparticle size and coating on radiosensitization and generation of reactive oxygen species in cancer therapy. Nanoscale Advances. 7(4). 1204–1214. 6 indexed citations
6.
Martín-Martín, Natalia, et al.. (2024). Metastatic hormone-naïve prostate cancer: a distinct biological entity. Trends in cancer. 10(9). 825–841. 3 indexed citations
7.
Mateo, Joaquı́n, et al.. (2024). A comparative study of sensitizers and liposome composition in radiation-induced controlled drug release for cancer therapy. Journal of Liposome Research. 35(1). 64–75. 2 indexed citations
8.
Lorenzin, Francesca, Francesco Orlando, Ubaldo Gioia, et al.. (2024). CRISPR/Cas9 screens identify LIG1 as a sensitizer of PARP inhibitors in castration-resistant prostate cancer. Journal of Clinical Investigation. 135(4). 2 indexed citations
9.
10.
Francini, Edoardo, Neeraj Agarwal, Elena Castro, et al.. (2024). Intensification Approaches and Treatment Sequencing in Metastatic Castration-resistant Prostate Cancer: A Systematic Review. European Urology. 87(1). 29–46. 9 indexed citations
11.
Morales‐Barrera, Rafael, Guillermo Villacampa, Teresa Bonfill, et al.. (2023). Prevalence of immune-related adverse events and anti-tumor efficacy in advanced/metastatic urothelial carcinoma following immune-checkpoint inhibitor treatment. Clinical & Translational Oncology. 25(12). 3556–3564. 1 indexed citations
12.
Mateo, Joaquı́n, Lotte Steuten, Philippe Aftimos, et al.. (2022). Delivering precision oncology to patients with cancer. Nature Medicine. 28(4). 658–665. 197 indexed citations breakdown →
13.
N., Kim, Alan Barnicle, Zhongwu Lai, et al.. (2022). Detection of BRCA1 , BRCA2 , and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound. Clinical Cancer Research. 29(1). 81–91. 46 indexed citations
14.
Kumar, Rajiv, Dionysis Papadatos-Pastos, Joaquı́n Mateo, et al.. (2020). First-in-Human Study of AT13148, a Dual ROCK-AKT Inhibitor in Patients with Solid Tumors. Clinical Cancer Research. 26(18). 4777–4784. 52 indexed citations
15.
Bono, Johann S. de, Joaquı́n Mateo, Karim Fizazi, et al.. (2020). Olaparib for Metastatic Castration-Resistant Prostate Cancer. New England Journal of Medicine. 382(22). 2091–2102. 1397 indexed citations breakdown →
16.
Hussain, Maha, Joaquı́n Mateo, Karim Fizazi, et al.. (2020). Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. New England Journal of Medicine. 383(24). 2345–2357. 474 indexed citations breakdown →
17.
Mateo, Joaquı́n, Christopher J. Lord, Violeta Serra, et al.. (2019). A decade of clinical development of PARP inhibitors in perspective. Annals of Oncology. 30(9). 1437–1447. 495 indexed citations breakdown →
18.
Nombela, Paz, Rebeca Lozano, Àlvaro Aytés, et al.. (2019). BRCA2 and Other DDR Genes in Prostate Cancer. Cancers. 11(3). 352–352. 67 indexed citations
19.
Rodrigues, Daniel Nava, Nicola Casiraghi, Alessandro Romanel, et al.. (2018). RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 25(2). 687–697. 44 indexed citations
20.
Mateo, Joaquı́n, Debyani Chakravarty, Rodrigo Dienstmann, et al.. (2018). A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Annals of Oncology. 29(9). 1895–1902. 391 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eleni Efstathiou Breakdown of academic impact, for papers by Kyung-Hun Lee Breakdown of academic impact, for papers by Rinat Yerushalmi Breakdown of academic impact, for papers by Daniele Generali Breakdown of academic impact, for papers by Przemyslaw Twardowski Breakdown of academic impact, for papers by Åslaug Helland Breakdown of academic impact, for papers by Binghe Xu Breakdown of academic impact, for papers by Niven Mehra Breakdown of academic impact, for papers by Eva Ciruelos Breakdown of academic impact, for papers by Martin Filipits
Rankless by CCL
2026